
Pelacarsen Failed To Meet Its Primary Endpoint, But The Science Keeps Going
Send us Fan Mail Cardiologists Dr. Seth Baum and Dr. Michael Koren discuss the newly released top-line results from a big Lp(a) study investigating the effects of the drug pelacarsen. They talk about what Lp(a) is, why it matters, happened in the study, and what this means for other pelacarsen and Lp(a) studies worldwide. They take a deep dive into some of the factors that can reduce the effectiveness of clinical trials and explain that this particular failure doesn't undermine the theory behind controlling Lp(a) levels or the potential effectiveness of competing investigational medications. Finally, the companion cardiologists talk about what this means for people who have high Lp(a) and what they can do to help control their risks of associated heart problems. Be a part of advancing science by participating in clinical research. Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.com Listen on Spotify Listen on Apple Podcasts Watch on YouTube Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram X (Formerly Twitter) LinkedIn Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com Music: Storyblocks - Corporate Inspired Thank you for listening!
- Transcript
- Chapters


















